scholarly journals Beneficial role of increased FOXP3+ regulatory T-cells in acute myeloid leukaemia therapy response

2017 ◽  
Vol 182 (4) ◽  
pp. 581-583 ◽  
Author(s):  
Thomas Menter ◽  
Boris Kuzmanic ◽  
Christoph Bucher ◽  
Michael Medinger ◽  
Joerg Halter ◽  
...  
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Therapy Response ◽  
Beneficial Role ◽  
Leukaemia Therapy ◽  
Acute Myeloid

The use of nanocarriers in acute myeloid leukaemia therapy: challenges and current status.

2015 ◽  
Vol 17 (1) ◽  
pp. 30-41 ◽  
Author(s):  
Félix Sauvage ◽  
Gillian Barratt ◽  
Lars Herfindal ◽  
Juliette Vergnaud-Gauduchon
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Current Status ◽  
Leukaemia Therapy ◽  
Acute Myeloid

scholarly journals Role of alternative polyadenylation dynamics in acute myeloid leukaemia at single-cell resolution

RNA Biology ◽  
2019 ◽  
Vol 16 (6) ◽  
pp. 785-797 ◽  
Author(s):  
Congting Ye ◽  
Qian Zhou ◽  
Yiling Hong ◽  
Qingshun Quinn Li
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Single Cell ◽  
Myeloid Leukaemia ◽  
Alternative Polyadenylation ◽  
Acute Myeloid

scholarly journals Endothelial E-selectin inhibition improves acute myeloid leukaemia therapy by disrupting vascular niche-mediated chemoresistance

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Valerie Barbier ◽  
Johanna Erbani ◽  
Corrine Fiveash ◽  
Julie M. Davies ◽  
Joshua Tay ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Vascular Niche ◽  
Leukaemia Therapy ◽  
Acute Myeloid

scholarly journals N6-Methyladenosine Role in Acute Myeloid Leukaemia

2018 ◽  
Vol 19 (8) ◽  
pp. 2345 ◽  
Author(s):  
Zaira Ianniello ◽  
Alessandro Fatica
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Cellular Differentiation ◽  
Normal Development ◽  
Rna Modifications ◽  
Deep Impact ◽  
Rna Molecules ◽  
Post Transcriptional Regulation ◽  
Acute Myeloid

We are currently assisting in the explosion of epitranscriptomics, which studies the functional role of chemical modifications into RNA molecules. Among more than 100 RNA modifications, the N6-methyladenosine (m6A), in particular, has attracted the interest of researchers all around the world. m6A is the most abundant internal chemical modification in mRNA, and it can control any aspect of mRNA post-transcriptional regulation. m6A is installed by “writers”, removed by “erasers”, and recognized by “readers”; thus, it can be compared to the reversible and dynamic epigenetic modifications in histones and DNA. Given its fundamental role in determining the way mRNAs are expressed, it comes as no surprise that alterations to m6A modifications have a deep impact in cell differentiation, normal development and human diseases. Here, we review the proteins involved in m6A modification in mammals, m6A role in gene expression and its contribution to cancer development. In particular, we will focus on acute myeloid leukaemia (AML), which provides an initial indication of how alteration in m6A modification can disrupt normal cellular differentiation and lead to cancer.

Mechanisms of Suppression Used by Regulatory T Cells in Patients Newly Diagnosed with Acute Myeloid Leukemia

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 2938-2938 ◽  
Author(s):  
Miroslaw J Szczepanski ◽  
Marta Szajnik ◽  
Malgorzata Czystowska ◽  
Magis Mandapathil ◽  
Ann Welsh ◽  
...  
Keyword(s):  
T Cells ◽  
Acute Myeloid Leukemia ◽  
Regulatory T Cells ◽  
Myeloid Leukemia ◽  
Neutralizing Antibodies ◽  
Hematologic Malignancies ◽  
Cell Contact ◽  
Newly Diagnosed ◽  
Acute Myeloid

Abstract An elevated frequency of CD4+CD25high regulatory T cells (Treg) has been reported in the peripheral blood in patients with various solid tumors and hematologic malignancies. Although the increase in Treg seems to be a characteristic feature of most tumors, the functional role of Treg and the mechanisms of suppression, especially in patients with hematologic malignancies, have been less well defined. We investigated Treg-mediated suppression and the responsible mechanisms in thirty newly diagnosed acute myeloid leukemia (AML) patients prior to any treatment and twenty five healthy donors (NC). The percentage of circulating CD4+ CD25high Treg was higher (p <0.0001) in the AML patients (4.5 ±0.2%, range 1.7–8.2%) compared to NC (1.5 ± 0.08%, range 0.9–3.1 %). To evaluate the suppressive function, CD4+CD25high T cells (S) were co-cultured with sorted, CFSE-labeled autologous CD4+CD25high T cells (R) at different S/R ratios. Suppression mediated by Treg co-incubated with proliferating autologous responders was significantly higher (p<0.001) in AML than that mediated by control Treg. To evaluate the role of cytokines produced by Treg in suppression and a need for cell-to- cell contact, transwell analysis of S/R co-cultures was performed. Co-incubation in the presence of transwell inserts (TRI) resulted in significant reduction of suppression (p<0.05), and the addition of neutralizing antibodies to IL-10 and TGF-β1 in the presence of TRI further decreased suppression mediated by Treg. These data suggest that both immunoinhibitory cytokine production and cell-to-cell contact are necessary for suppression. To explore other potential mechanisms of Treg suppression, we evaluated the expression by Treg of ectonucleotidases CD39 and CD73 and the capability of Treg to produce adenosine. CD4+CD25high T cells of AML patients had higher expression (p<0.01) of CD39 and more efficiently hydrolyzed ATP to adenosine relative to Treg in NC. These data indicate that various mechanisms of suppression may be utilized by Treg in patients with AML. The increase frequency of Treg mediating potent suppression by various mechanisms is likely to play a role in host anti-tumor immune responses. Therefore, modulation of the frequency and functions of Treg might provide new immunotherapeutic approaches in AML.

Efficacy and feasibility of intensive induction therapy in very elderly patients with acute myeloid leukaemia

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 16528-16528
Author(s):  
G. Biaggi ◽  
A. Santagostino ◽  
D. Manachino ◽  
T. Posca ◽  
G. Forti ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Performance Status ◽  
Best Supportive Care ◽  
Induction Treatment ◽  
Very Elderly ◽  
Ecog Performance Status ◽  
Leukaemia Therapy ◽  
Acute Myeloid

16528 Background: Intensive Induction Treatment (IIT) increases chances of longer survival in acute myeloid leukaemia (AML). Our aim was to improve outcome and to evaluate safety and tolerability of IIT in very elderly patients (pts). Otherwise they have a median surviving time of 11 weeks without treatment. Methods: From October 2003 to November 2005 we treated 23 pts, 16 Males (M) and 7 Female (F); median age 75.5 years (range 68–95). According FAB classification they were 1 M0, 10 M1, 5 M2, 6 M4, 1 M5. ECOG performance status (PS) was 0 in 6 pts, 1 in 5 pts, 2 in 7 pts and 3 in 5 pts. All pts underwent IIT with different schedules: only a female 95 years old had less intensive treatment. Immune-chemotherapy was also admitted. Schedules were: 3+7 IDA+ARA-C in 8 pts; MY-FLAI in 7 pts; VP+ARA-C 1 = ≥ 5 in 2 pts; IDA+ARA-C 1 = ≥ 2 in 4 pts; ARA-C + 6TG in 1 pt. Eleven pts underwent second line treatment. Results: Five pts are alive and 18 dead. We obtained 7 complete responses (CR) (32%) and 1 partial response (PR) (RR 36%);. The median CR duration was 7.5 months (range 1–12).Throughout IIT we observed 5 toxic deaths (23%) because of infections and 2 deaths not leukaemia therapy related (heart failure). The median Overall Survival (OS) was 9 months. Conclusions: Despite the toxic deaths due to the treatment, we obtained in 32% of the pts CR longer compared to palliative or best supportive care; also the median OS was longer than we can expected without chemotherapy. Our data support in our opinion the feasibility and the utility of an IIT in very elderly patients with good PS. No significant financial relationships to disclose.

The role of intensive remission induction and consolidation therapy in patients with acute myeloid leukaemia

1987 ◽  
Vol 66 (1) ◽  
pp. 37-44 ◽  
Author(s):  
G. Tricot ◽  
M. A. Boogaerts ◽  
R. Vlietinck ◽  
M. P. Emonds ◽  
R. L. Verwilghen
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Remission Induction ◽  
Consolidation Therapy ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document